Asana BioSciences, a clinical-stage biopharmaceutical company focused on the discovery and development of novel targeted therapies in inflammation/immunology and oncology, announced positive topline results from a Phase 1b double-blind, vehicle-controlled, dose escalation trials evaluating their sodium channel blocker, ASN008, for the treatment of pruritus in atopic dermatitis.
ASN008 is a novel topical sodium channel blocker with a unique mechanism of action. ASN008 selectively blocks the activity of itch- and pain-sensing afferent neurons without affecting motor neurons.
A single application of ASN008 achieved a clinically meaningful reduction in pruritus in 2-3 hours, and this effect lasted greater than 8 hours. The anti-pruritic effect of ASN008 was maintained with daily application of ASN008 for two weeks. ASN008 demonstrated low systemic exposure, and safety results show that it was well tolerated with only mild adverse events.
Read more about Asana BioSciences here.
Photo by Kristina Paukshtite from Pexels
